Overview

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Activity of Intravitreal LKA651 in Patients With Macular Edema

Status:
Completed
Trial end date:
2018-02-15
Target enrollment:
Participant gender:
Summary
To evaluate the safety and tolerability of LKA651 in patients with macular edema from diabetic macular edema (DME), neovascular age-related macular degeneration (AMD), or retinal vein occlusions (RVO)
Phase:
Phase 1
Details
Lead Sponsor:
Novartis Pharmaceuticals